The Advertising Standards Authority (ASA) has banned five adverts for supplements that claimed to treat symptoms of menopause and other women’s hormonal issues. This decision underscores the importance of accurate health information, particularly for vulnerable populations.
Among the brands affected are 222 Balance Me, Lunera, Minerva, and Nova Menopause Vitality, all of which made claims that their products could prevent, treat, or cure menopause symptoms. Additionally, an ad for PolyBiotics implied that their supplements could prevent, cure, or treat polycystic ovary syndrome (PCOS).
The ASA utilized artificial intelligence to analyze health claims in online advertisements, leading to the conclusion that many assertions made in these ads were unacceptable. The authority emphasized that misleading claims could pose real risks to individuals seeking help for their health concerns.
Catherine Drewett, a representative from the ASA, stated, “People deserve clear and accurate information.” She further noted that misleading advertisements regarding the treatment of menopause, PCOS, and other hormonal conditions could cause significant harm.
In response to the ASA’s findings, 222 Collective acknowledged that the wording in their ads might have inadvertently suggested that their product could alleviate symptoms related to PMS and menopause. Similarly, Lunera accepted that their claims could be interpreted by consumers as attributing medicinal properties to a food supplement.
PolyBiotics also conceded that references to PCOS and associated symptoms constituted disease treatment claims, which are not permitted for food supplements under current regulations.
The ASA’s scrutiny reflects a broader concern about advertisements that may exploit individuals’ health worries, emotional concerns, or financial pressures. This proactive approach aims to protect consumers from potentially harmful misinformation.
As the landscape of health advertising continues to evolve, further developments are expected regarding the regulation of health claims in marketing. Details remain unconfirmed regarding any potential changes to advertising guidelines or additional actions that may be taken against other brands.
